Zithromax comes to replace penicillin in the treatment of angina
Unique pharmacokinetic characteristics (accumulation in the tissues, metabolic stability, unique to long half-life), a wide spectrum of antibacterial activity, including atypical pathogens, the presence of postantibiotic effect, good tolerability, high compliance, low level of resistance of pathogens, the presence of anti-inflammatory and antioxidant activity - all this gives grounds for the widespread use of Zithromax for respiratory infections. Clinical efficacy of Zithromax for empirical treatment of bronchopulmonary infections (as monotherapy and in combination with β-lactams) in the outpatient and inpatient proved in a number of multicenter studies.
According to French scientists from the hospital Intercommunal de Creteil, Zithromax is more effective and better tolerated than penicillin in the treatment of acute streptococcal tonsillitis pharyngitis.
Currently, standard treatment of pharyngitis caused by beta - hemolytic streptococcus groups A included ten-day course of drugs from the penicillin group. It is believed that such treatment helps to prevent rheumatic fever and streptococcal infections. However, at present more than one third of patients (Especially children under 6 years) this regimen is not effective due to the stability of the streptococcus to penicillin.
The proposed scheme of treatment of streptococcal infections is the appointment of Zithromax at a dose of 12mg/kg for five days or 20mg/kg for three days. Such regimen is more effective, as streptococci are less resistant to Zithromax.